“We believe these preclinical results underscore the exciting therapeutic potential unlocked by our di-siRNA platform ... central nervous system using RNA interference. Atalanta’s unique ...

BOSTON, April 08, 2025--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi ... of its investigational di-siRNA therapy, ATL-201, in a mouse model ...

About RNAi Therapeutics RNAi (RNA interference) is a natural cellular ... Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform ...

SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate.

In particular, hedge fund managers, using their vast resources and analytical capabilities, are more receptive to such ...

​This article will examine 20 takeover rumors that have prompted hedge funds to buy stocks.

siRNA: short strands of RNA that are also part of the RNA interference pathway, however, are specific to a single target mRNA. Also includes antisense oligonucleotides (ASO). Antisense ...

As a small interfering RNA (siRNA) drug, Qfitlia mimics a natural ... Qfitlia is the second RNA interference drug to score a highly anticipated FDA nod in recent days. Last week, the agency ...

Small nucleic acid drugs, such as siRNA, anti-sense oligonucleotides (ASO), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

RNAi (RNA interference) is a biological process in which RNA molecules—microRNA (miRNA) and small interfering RNA (siRNA)—inhibit gene expression, typically by binding to messenger RNA (mRNA ...

The most recent addition to the methods hall of fame is RNA interference (RNAi ... with new modes of siRNA action still emerging, so we are not setting the criteria for publication in stone.